Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BridgeBio Oncology Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $387.22 Mil.
BridgeBio Oncology Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-198.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Oncology Therapeutics EV-to-EBIT Related Terms
BridgeBio Oncology Therapeutics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Oncology Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BridgeBio Oncology Therapeutics's EV-to-EBIT falls into.
BridgeBio Oncology Therapeutics's current Enterprise Value is $504.98 Mil.
BridgeBio Oncology Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-198.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Oncology Therapeutics (BBOT) has a EV-to-EBIT of -2.54 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 367 companies in the Biotechnology industry.
Is BridgeBio Oncology Therapeutics' EV-to-EBIT too high?
BridgeBio Oncology Therapeutics' current EV-to-EBIT is -2.54. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 367 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' EV-to-EBIT compare to CTMX and OMER?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 367 companies for EV-to-EBIT. This places BridgeBio Oncology Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.96, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BridgeBio Oncology Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Oncology Therapeutics's current EV-to-EBIT is -2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current EV-to-EBIT of -2.54. The current EV-to-EBIT is -2.54. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current EV-to-EBIT is -2.54 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score
Get the complete analysis for BBOT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBOT has been successfully added to your 
